Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
17 04 2023
Historique:
received: 11 03 2022
accepted: 04 04 2023
medline: 19 4 2023
entrez: 17 4 2023
pubmed: 18 4 2023
Statut: epublish

Résumé

Mitochondria are hubs where bioenergetics, redox homeostasis, and anabolic metabolism pathways integrate through a tightly coordinated flux of metabolites. The contributions of mitochondrial metabolism to tumor growth and therapy resistance are evident, but drugs targeting mitochondrial metabolism have repeatedly failed in the clinic. Our study in pancreatic ductal adenocarcinoma (PDAC) finds that cellular and mitochondrial lipid composition influence cancer cell sensitivity to pharmacological inhibition of electron transport chain complex I. Profiling of patient-derived PDAC models revealed that monounsaturated fatty acids (MUFAs) and MUFA-linked ether phospholipids play a critical role in maintaining ROS homeostasis. We show that ether phospholipids support mitochondrial supercomplex assembly and ROS production; accordingly, blocking de novo ether phospholipid biosynthesis sensitized PDAC cells to complex I inhibition by inducing mitochondrial ROS and lipid peroxidation. These data identify ether phospholipids as a regulator of mitochondrial redox control that contributes to the sensitivity of PDAC cells to complex I inhibition.

Identifiants

pubmed: 37069167
doi: 10.1038/s41467-023-37924-9
pii: 10.1038/s41467-023-37924-9
pmc: PMC10110566
doi:

Substances chimiques

Reactive Oxygen Species 0
Phospholipid Ethers 0
Phospholipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

2194

Subventions

Organisme : NCI NIH HHS
ID : P50CA221707
Pays : United States
Organisme : NCI NIH HHS
ID : P01CA117969
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA248160
Pays : United States
Organisme : NIH HHS
ID : S10OD012304-01
Pays : United States
Organisme : NIH HHS
ID : P01CA117969
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA214793
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA258917
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA244931
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Dev Cell. 2020 Aug 24;54(4):447-454.e4
pubmed: 32652074
Protein Cell. 2018 Feb;9(2):196-206
pubmed: 28523433
Nature. 2021 Nov;599(7884):302-307
pubmed: 34671163
Free Radic Biol Med. 2011 Apr 1;50(7):892-8
pubmed: 21236336
Br J Cancer. 2019 Jun;120(12):1090-1098
pubmed: 31092908
Free Radic Biol Med. 2015 Dec;89:883-94
pubmed: 26454075
Annu Rev Med. 2015;66:17-29
pubmed: 25386929
J Biol Chem. 2002 Nov 22;277(47):44784-90
pubmed: 12237311
Mol Cell Biol. 2015 Apr;35(7):1139-56
pubmed: 25605331
Toxicol In Vitro. 2020 Sep;67:104907
pubmed: 32502624
J Exp Clin Cancer Res. 2018 Nov 1;37(1):266
pubmed: 30382874
Nature. 2014 Oct 30;514(7524):628-32
pubmed: 25119024
Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):919-22
pubmed: 11072146
Cell Rep. 2020 Oct 6;33(1):108231
pubmed: 33027658
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Biochim Biophys Acta. 2012 Sep;1822(9):1442-52
pubmed: 22627108
Prog Lipid Res. 2004 Mar;43(2):91-104
pubmed: 14654089
Cell Metab. 2020 Sep 1;32(3):341-352
pubmed: 32668195
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Rep. 2016 Jun 28;16(1):133-147
pubmed: 27320920
Antioxid Redox Signal. 2011 Sep 15;15(6):1583-606
pubmed: 21473702
Clin Cancer Res. 2018 Jun 1;24(11):2482-2490
pubmed: 29420223
Nat Chem Biol. 2021 Jun;17(6):703-710
pubmed: 33723432
Cell Metab. 2016 Oct 11;24(4):582-592
pubmed: 27667666
Signal Transduct Target Ther. 2020 Nov 24;5(1):273
pubmed: 33235217
Biochim Biophys Acta Bioenerg. 2017 Aug;1858(8):686-699
pubmed: 28161329
Cell Death Dis. 2020 Feb 6;11(2):105
pubmed: 32029741
Nat Chem Biol. 2020 Dec;16(12):1351-1360
pubmed: 32778843
Cell Metab. 2017 Apr 4;25(4):765-776
pubmed: 28380371
Lab Invest. 2015 Feb;95(2):207-22
pubmed: 25485535
Cell. 2015 Oct 8;163(2):340-53
pubmed: 26451484
JCI Insight. 2019 Nov 1;4(21):
pubmed: 31557131
Biochim Biophys Acta. 1999 Jan 4;1436(3):265-78
pubmed: 9989259
Adv Exp Med Biol. 2018;1072:393-397
pubmed: 30178377
Neurochem Int. 2006 Sep;49(4):379-86
pubmed: 16580092
Nature. 2020 Sep;585(7826):603-608
pubmed: 32939090
Cell. 2020 Apr 30;181(3):716-727.e11
pubmed: 32259488
Oncol Lett. 2012 Dec;4(6):1151-1157
pubmed: 23226794
Curr Protoc Mouse Biol. 2016 Mar 01;6(1):1-14
pubmed: 26928661
Bioorg Med Chem Lett. 2008 Aug 1;18(15):4298-302
pubmed: 18632269
Nat Rev Cancer. 2021 Dec;21(12):753-766
pubmed: 34417571
Nat Med. 2018 Jul;24(7):1036-1046
pubmed: 29892070
Int J Mol Sci. 2017 May 24;18(6):
pubmed: 28538669
Mitochondrion. 2019 Nov;49:259-268
pubmed: 31207408
Cell Metab. 2020 Mar 3;31(3):642-653.e6
pubmed: 32130885
Cancer Cell. 2019 May 13;35(5):798-815.e5
pubmed: 31031016
Oncotarget. 2018 May 18;9(38):24980-24991
pubmed: 29861847
Cell Rep Med. 2020 Nov 17;1(8):100143
pubmed: 33294863
Cell Chem Biol. 2019 Mar 21;26(3):309-311
pubmed: 30901556
J Biol Chem. 2003 Dec 26;278(52):52873-80
pubmed: 14561769
Cell Chem Biol. 2019 Mar 21;26(3):420-432.e9
pubmed: 30686757
Cells. 2019 Nov 21;8(12):
pubmed: 31766580
Nat Struct Mol Biol. 2017 Oct 5;24(10):800-808
pubmed: 28981073

Auteurs

Ziheng Chen (Z)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ZChen13@mdanderson.org.

I-Lin Ho (IL)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Melinda Soeung (M)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Er-Yen Yen (EY)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jintan Liu (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Liang Yan (L)

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Johnathon L Rose (JL)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Translational Research to AdvanCe Therapeutics and Innovation in ONcology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Sanjana Srinivasan (S)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Translational Research to AdvanCe Therapeutics and Innovation in ONcology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Shan Jiang (S)

Translational Research to AdvanCe Therapeutics and Innovation in ONcology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Q Edward Chang (Q)

The Oncology Research for Biologics and Immunotherapy Translation (ORBIT), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ningping Feng (N)

Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jason P Gay (JP)

Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Qi Wang (Q)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jing Wang (J)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Philip L Lorenzi (PL)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lucas J Veillon (LJ)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Bo Wei (B)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

John N Weinstein (JN)

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Angela K Deem (AK)

Translational Research to AdvanCe Therapeutics and Innovation in ONcology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Sisi Gao (S)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Giannicola Genovese (G)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Andrea Viale (A)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Wantong Yao (W)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, University of Texas, Houston, TX, USA.

Costas A Lyssiotis (CA)

Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI, 48109, USA.
University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48109, USA.
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI, 48109, USA.

Joseph R Marszalek (JR)

Translational Research to AdvanCe Therapeutics and Innovation in ONcology (TRACTION), The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Giulio F Draetta (GF)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. GDraetta@mdanderson.org.
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. GDraetta@mdanderson.org.

Haoqiang Ying (H)

Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. hying@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH